Harvard Mental Health Letter

In brief: Antipsychotic choice in early-onset schizophrenia

In brief

Antipsychotic choice in early-onset schizophrenia

Another study raises questions about the relative efficacy of first- and second-generation antipsychotics.

In the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study, investigators randomly assigned 119 patients, ages 8 to 19, diagnosed with early-onset schizophrenia or schizoaffective disorder to treatment with the first-generation drug molindone (Moban) or one of two second-generation drugs, olanzapine (Zyprexa) or risperidone (Risperdal). Some patients were just diagnosed or "first episode," while others had chronic illness. Medications were prescribed at moderate doses.

To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »